Aim. Carry out a meta-analysis of randomized controlled clinical trials of the effectiveness of riamilovir (Triazavirin®) in the etiotropic therapy of acute respiratory viral infection in adults and school-age children (6-17 years old). Material and methods. The meta-analysis was performed in accordance with the PRISMA principles for the quality of presentation of information on the results of systematic reviews and meta-analyses devoted to the evaluation of medical interventions. According to the search results in PubMed databases, eLIBRARY. ru and cyberleninka.ru at the request of «triazavirin», «riamilovir», «triazavirin», «riamilovir» and the analysis of compliance with the inclusion criteria, 4 papers were selected. As a result, the analysis included 949 patients from 31 centers with a confirmed diagnosis of acute respiratory viral infection and laboratory-confirmed absence of influenza virus antigens. The effectiveness of riamilovir (Triazavirin®, capsules 100 and 250 mg) in daily doses of 500 and 750 mg in adult patients, at a dose of 500 mg per day in adolescents aged 12-17 years and at a dose of 200 mg per day in children aged 6-11 years compared with placebo, was evaluated for 5 days of treatment. Results. A meta-analysis confirmed a significant association between the use of riamilovir (Triazavirin®) and the chance of a sustained improvement in clinical symptoms on day 5 of treatment. Therapy with riamilovir (Triazavirin®) compared with placebo has a statistically significant difference in the proportion of patients with normalization of body temperature by the 5th day after the start of therapy, and the proportion of patients with complete disappearance of all symptoms by the end of the 5th day after the start of therapy was 6 times higher than in the Placebo group. Conclusion. A meta-analysis of randomized multicenter, double-blind clinical trials of the efficacy and safety of etiotropic ARVI therapy in school-age children (6-17 years old) and adults showed the reliability of the established effectiveness of antiviral therapy with riamilovir (Triazavirin®) in patients, therefore, the drug can be recommended as a first-line etiotropic therapy in adult and pediatric patients with respiratory viral diseases.